logo
Plus   Neg
Share
Email

Live Nation Buys Premier U.S. Promoter Red Mountain Entertainment

Live Nation Entertainment said that it has acquired a majority stake in Red Mountain Entertainment, one of the premier regional concert and festival promoters in the United States.

The companies plan to combine Red Mountain's rich market expertise with Live Nation's extensive resources to continue growing live entertainment offerings throughout the Southeastern United States.

Red Mountain will continue to oversee all operations for its diverse suite of events and projects, which range from concert promotions, to festival promotion and production, as well as venue consulting. The core concert promotions business handles show bookings in venues ranging from amphitheaters and arenas to clubs and theatres, including exclusive venues The Wharf Amphitheater, Tuscaloosa Amphitheater, Brandon Amphitheater, and Iron City.

Additionally, Red Mountain is actively involved in the production of music festivals throughout the Southeast including Sloss Music & Arts Festival, which the company co-owns with AC Entertainment and VMI, and has exclusive booking partnerships with Beale Street Music Festival in Memphis and Wildflower! Arts & Music Festival in Richardson, TX. In addition, Red Mountain produces craft beer festivals in the Southeast and owns the Oak Mountain State Fair in Pelham, Alabama.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>